Can Obama Help Vete...
Health Care: Drugs
AstraZeneca PLC (AZN: NYSE)
$40.08 -0.33 | -0.82%
06/01/12 - 04:01 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 7.57B | 11.07B | 9.92B | 4.29B |
| Receivables | 9.81B | 10.89B | 10.58B | 9.16B |
| Inventories | 1.85B | 1.68B | 1.75B | 1.64B |
| Other Current Assets | 25.00M | 9.00M | 0.00 | 0.00 |
| Total Current Assets | 23.51B | 25.13B | 23.76B | 16.15B |
| Property, Plant & Equipment, Gross | 15.31B | 15.58B | 15.17B | 14.61B |
| Accumulated Depreciation & Depletion | 8.88B | 8.63B | 7.86B | 7.57B |
| Property, Plant & Equipment, Net | 6.42B | 6.96B | 7.31B | 7.04B |
| Intangibles | 10.98B | 12.16B | 12.23B | 12.32B |
| Other Non-Current Assets | 543.00M | 535.00M | 446.00M | 156.00M |
| Total Non-Current Assets | 29.32B | 31.00B | 31.16B | 30.63B |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 52.83B | 56.13B | 54.92B | 46.78B |
| Accounts Payable | 8.98B | 8.66B | 8.69B | 3.90B |
| Short Term Debt | 1.99B | 125.00M | 1.93B | 993.00M |
| Other Current Liabilities | 4.79B | 8.00B | 7.03B | 6.55B |
| Total Current Liabilities | 15.75B | 16.79B | 17.64B | 13.32B |
| Long Term Debt | 7.34B | 9.47B | 244.00M | 10.86B |
| Deferred Income Taxes | 2.74B | 3.14B | 3.25B | 3.13B |
| Other Non-Current Liabilities | 3.53B | 3.32B | 12.97B | 3.42B |
| Minority Interest | 33.00M | 28.00M | 23.00M | 29.00M |
| Total Non-Current Liabilities | 13.83B | 16.13B | 16.62B | 17.55B |
| Total Liabilities | 29.58B | 32.91B | 34.26B | 30.87B |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 23.25B | 23.21B | 20.66B | 15.91B |
| Common Par | 323.00M | 352.00M | 363.00M | 362.00M |
| Additional Paid In Capital | 3.08B | 2.67B | 2.18B | 2.05B |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | 17.89B | 18.27B | 16.20B | 11.57B |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 1.95B | 1.92B | 1.92B | 1.93B |
| Total Capitalization | 30.58B | 32.68B | 20.90B | 26.77B |
| Total Equity | 23.25B | 23.21B | 20.66B | 15.91B |
| Total Liabilities & Stock Equity | 52.83B | 56.13B | 54.92B | 46.78B |
| Total Common Shares Outstanding | 1.29B | 1.41B | 1.45B | 1.45B |
| Preferred Shares | 50.00K | 50.00K | 50.00K | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 1.36B | 1.44B | 1.45B | 1.45B |
| Diluted Weighted Shares Outstanding | 1.37B | 1.45B | 1.45B | 1.45B |
| Number of Employees | 57200 | 61000 | 63000 | 66100 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with AZN
- Portfolio NameUser Type
- UserGFNN Stockdiagnostics 14
- UserThe Coming M&A boom
- ContributorHighest-Yielding Drug Stocks
- Contributor10 Dividend Stocks Still Pa...
- User2012 performers
- Contributor6 European Stocks Resistant...
- UserMoney Maker
- Userkeithj
- ContributorRocket Stocks for the Week ...
- ProJohn Hussman
Latest AZN Headlines from TheStreet
- 9 High-Yield Stocks to Consider in Lieu of Bonds 06.01.12 | 01:06 pm
- AstraZeneca PLC (AZN): Today's Featured Health Care Winner 05.03.12 | 05:05 pm
- The Next Big Thing in Biotech: M&A
04.27.12 | 05:04 am - AstraZeneca PLC (AZN): Today's Featured Drugs Loser 04.26.12 | 05:04 pm
- Rupert Murdoch in Second Day of Testimony: Hot Trends 04.26.12 | 08:04 am
- 14 Deal-Ready Stocks for the M&A Boom 04.26.12 | 06:04 am
- AstraZeneca Buys Ardea Biosciences for $1.26 Billion: Hot Trends 04.23.12 | 10:04 am
- AstraZeneca Buys Ardea Biosciences for $1.26B: Hot Trends 04.23.12 | 08:04 am
- AstraZeneca Wins Patent Protection on Seroquel: Hot Trends 03.30.12 | 10:03 am
- Stocks to Watch: Research In Motion, Dunkin' Brands (Update 1) 03.30.12 | 08:03 am
Press Releases for AZN
- Data Presented At The European Atherosclerosis Society Congress Reinforces The Differentiating Benefits Of CRESTOR[TM] In Comparison To Atorvastatin And Simvastatin - PR Newswire 05.28.12 | 01:05 am
- SYMBICORT® (budesonide/formoterol Fumarate Dihydrate) Long-Term Study Shows Similar Safety Profile When Compared To Budesonide Monotherapy In African-American Patients With Asthma - Business Wire 05.10.12 | 09:05 am
- LUNAR Examines Cholesterol-Lowering Effects Of CRESTOR® (rosuvastatin Calcium) Compared With Atorvastatin In Patients With Acute Coronary Syndrome - Business Wire 05.01.12 | 09:05 am
- AstraZeneca And The Medicines Company Announce Global Collaboration In Acute Ischemic Heart Disease - Business Wire 04.25.12 | 12:04 pm
- AstraZeneca Launches DUTOPROL™ (metoprolol Succinate Extended Release/hydrochlorothiazide) Tablets For High Blood Pressure In U.S. - Business Wire 04.12.12 | 09:04 am
- US District Court Finds SEROQUEL XR Formulation Patent Valid And Infringed - Business Wire 03.29.12 | 05:03 pm
- Crestor Delivers Latest LDL-C Targets In High-Risk Patients At Lower Doses Than Other Statins - PR Newswire 03.26.12 | 01:03 pm
- US Court Denies Preliminary Injunction Application Against The FDA And Dismisses AstraZeneca’s Lawsuit Without Prejudice - Business Wire 03.26.12 | 02:03 am
- New Data Suggests Results Of PLATO Genetic Sub-Study Outcomes For BRILINTA® (Ticagrelor) Not Driven By Poor Metabolizers Of Clopidogrel - Business Wire 03.25.12 | 11:03 am
- New Data Suggests BRILINTA® (ticagrelor) Reduced First And Recurrent Cardiovascular And Ischemic Events - Business Wire 03.25.12 | 11:03 am
Partner Headlines for AZN
- Healthcare Biz Recap: Aeterna Zentaris Shares Surge, J&J Files with FDA - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- Analyst Insights: Finish Line, BioMarin Pharma, Laboratory Corp, Ocz Technology, AstraZeneca May 31st - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- 6 FTSE100 6%+ Dividend Yielders - Seeking Alpha 05.20.12 | 08:05 am
- Merger Arbitrage Mondays - May 14, 2012 - Seeking Alpha 05.14.12 | 09:05 am
- 4 New Reasons To Be Bullish On Sanofi Now - Seeking Alpha 05.13.12 | 09:05 am
- This Developmental Pharma Has Potential To Be A Long Term Multibagger - Seeking Alpha 05.03.12 | 09:05 am
- Spectrum: Increased Fusilev Production May Boost Stock - Seeking Alpha 04.30.12 | 09:04 am
- Benzinga's M&A Chatter for Friday April 27, 2012 - Benzinga 04.28.12 | 08:04 pm
- Earnings Recap for April 26, 2012 - Benzinga 04.26.12 | 09:04 am
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
